ARTICLE | Clinical News
FDA approves Genentech's Alecensa for first-line NSCLC
November 10, 2017 8:42 PM UTC
The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved an sNDA for Alecensa alectinib (AF802, CH5424802, RG7853, RO5424802) as first-line treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). FDA also converted to full approval its accelerated approval of Alecensa to treat ALK-positive, metastatic NSCLC in patients who have progressed on or are intolerant to Xalkori crizotinib...
BCIQ Target Profiles